These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454 [TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Krishnamurti C; Barr CF; Hassett MA; Young GD; Alving BM Blood; 1987 Mar; 69(3):798-803. PubMed ID: 3101764 [TBL] [Abstract][Full Text] [Related]
9. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis. Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465 [TBL] [Abstract][Full Text] [Related]
10. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. Sherman DG; Atkinson RP; Chippendale T; Levin KA; Ng K; Futrell N; Hsu CY; Levy DE JAMA; 2000 May; 283(18):2395-403. PubMed ID: 10815082 [TBL] [Abstract][Full Text] [Related]
11. The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis. Omran SA; Madkour BA; Essawy FM; Toima SM; el Kaliouby AH; Shams el Din AA Blood Coagul Fibrinolysis; 1992 Dec; 3(6):819-22. PubMed ID: 1489902 [TBL] [Abstract][Full Text] [Related]
12. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987 [TBL] [Abstract][Full Text] [Related]
13. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology. Forbes CD; Barbenell J; Prentice CR Haemostasis; 1976; 5(6):348-54. PubMed ID: 1017726 [TBL] [Abstract][Full Text] [Related]
14. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism]. Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724 [TBL] [Abstract][Full Text] [Related]
15. Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod. Kant KS; Pollak VE; Dosekun A; Glas-Greenwalt P; Weiss MA; Glueck HI J Lab Clin Med; 1985 Jan; 105(1):77-88. PubMed ID: 3968467 [TBL] [Abstract][Full Text] [Related]
16. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome. Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
18. Use of ancrod in acute or progressing ischemic cerebral infarction. Olinger CP; Brott TG; Barsan WG; Hedges JR; Glas-Greenwalt P; Pollak VE; Spilker J; Eberle R Ann Emerg Med; 1988 Nov; 17(11):1208-9. PubMed ID: 3056131 [TBL] [Abstract][Full Text] [Related]